[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].

Article Details

Citation

Copy to clipboard

Delbaldo C

[Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].

Therapie. 2007 Mar-Apr;62(2):87-90. Epub 2007 Jun 21.

PubMed ID

17582306 [ View in PubMed

]

Abstract

Imatinib (Glivec) is a specific inhibitor of tyrosine kinase receptor, in particular of the proto-oncogene c-kit. Proto-oncogene c-kit is expressed or mutated in stromal digestive tumors (GIST). Pharmacokinetic (PK) analysis showed that imatinib displayed linear PK in patients with advanced GIST. Imatinib is extensively metabolized by the cytochrome P450 enzyme system. Alpha-1-acid glycoprotein (AAG), a protein involved in the acute phase of inflammation, is implicated in protein binding of imatinib and seems to play a key role in imatinib PK.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Imatinib	High affinity nerve growth factor receptor	Protein	Humans	Unknown	Antagonist	Details